Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080221 · ClinicalTrials.gov registry record · Phase 2
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
A Phase 2 study of Metastatic Pancreatic Cancer, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT02080221 is a Phase 2 study of Metastatic Pancreatic Cancer that has completed, run by Brown University. The registered enrollment target is 50 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02080221, a Phase 2 study of Metastatic Pancreatic Cancer, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan). In this study you will receive the chemotherapy treatment FOLFOX-A (fluorouracil, oxaliplatin, leucovorin and Abraxane ®) which substitutes irinotecan for the FDA approved chemotherapy drug Abraxane ®. Even though Abraxane is FDA approved for pancreatic cancer, the combination of Abraxane with the other 3 drugs is being investigated. Your doctors are studying the activity and side effects of FOLFOX-A in advanced (metastatic) pancreatic cancer.
Conditions Studied
Interventions
- DRUG FOLFOXA
Study Locations (2)
Massachusetts
- Southcoast centers for cancer care - Fairhaven
Rhode Island
- Lifespan Hospitals (The Miriam and RI Hospital, East Greenwich, Newport) - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-08 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02080221
The ClinicalTrials.gov registry entry for NCT02080221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (53% lower). The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which FOLFOXA is the first listed.
NCT02080221 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT02080221 about?
NCT02080221 is a clinical study titled "BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial". A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan). In this study you will receive the chemotherapy treatment FOLFOX-A (fluorouracil, oxaliplatin, leucovorin and Abraxane ®) which substitu...
What is the current status of trial NCT02080221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-08. Estimated completion is 2022-03-16.
What conditions does trial NCT02080221 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT02080221?
The interventions under investigation include: FOLFOXA (DRUG).
Who is sponsoring clinical trial NCT02080221?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02080221 being conducted?
This trial has 2 study locations across Massachusetts, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
RECRUITING · Phase 2
-
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.